Johnson & Johnson has joined Pfizer and Moderna in their commitment to the US to provide a total of 240 million vaccine doses by the end of March. The drug companies told a House subcommittee this week that they expect to deliver this amount of doses after Johnson & Johnson pledged to add 20 million additional doses to Pfizer and Moderna’s 220 million dose pledge should the company receive emergency use authorization from the US Food and Drug Administration this week.
Dr. Richard Nettles is J&J’s vice president of medical affairs who spoke with the lawmakers regarding the company’s pledge should they receive the EUA as expected.
“If the emergency use authorization is received as expected this week, we hope to contribute to ending this pandemic as soon as possible.”
Nettles claims that the company is prepared to ship out 4 million doses immediately upon authorization of the vaccine. Executives from each of the vaccine makers testified before the House Committee on Energy and Commerce Subcommittee on Oversight and Investigations this past Tuesday.
If AstraZeneca secures an FDA authorization as well it will become the fourth Covid-19 vaccine available in the US. Dr. Ruud Dobber, the executive vice president and president of AstraZeneca’s biopharmaceuticals business unit, said the company “will immediately release 30 million doses upon authorization of the vaccine and up to 50 million doses by the end of April.”
Pfizer initially planned to deliver up to 40 million doses of their vaccine by the end of 2020, however, they just reached that milestone last week. Moderna was close to reaching their goal of 20 million doses by the end of 2020 but fell short by just a week. Executives for the companies claimed that a lack of access to raw materials and manufacturing a product that has never been made before were the main issues in production. John Young, Pfizer’s chief business officer, recently spoke about this issue to the media.
“We did initially experience some problems with the initial ramp up of our vaccine. We particularly saw some rate-limiting steps for raw materials.”
“We ultimately had never–when we were trying to make those estimates — manufactured at this scale, and so we had a lot to learn along the way. As we look back, could we have maybe started earlier in that process and lining up all of the critical raw materials sooner, would we have been able to get there a little bit faster instead of the first week of January, last week of December? It’s possible. Certainly hindsight, and that is 20-20 for us,” said Moderna’s president Dr. Stephen Hoge.
Moderna is currently seeking FDA approval for increasing the number of doses in each Covid-19 vaccine vial from 10 to 15. Hodge claims this would “accelerate delivery substantially and decrease the demand for some critical, high-demand raw materials. Obviously, any gains — for instance, filling more doses in a vial — we will take. We need to get more doses more quickly into peoples’ arms.”
Johnson & Johnson will be finding out if they receive an emergency use authorization this Friday.
Eric Mastrota is a Contributing Editor at The National Digest based in New York. A graduate of SUNY New Paltz, he reports on world news, culture, and lifestyle. You can reach him at email@example.com.